|
1
|
McDowell HP: Update on childhood
rhabdomyosarcoma. Arch Dis Child. 88:354–357. 2003. View Article : Google Scholar
|
|
2
|
Pappo AS, Shapiro DN, Crist WM and Maurer
HM: Biology and therapy of pediatric rhabdomyosarcoma. J Clin
Oncol. 13:2123–2139. 1995.PubMed/NCBI
|
|
3
|
Wolden SL, Anderson JR, Crist WM, Breneman
JC, Wharam MD Jr, Wiener ES, Qualman SJ and Donaldson SS:
Indications for radiotherapy and chemotherapy after complete
resection in rhabdomyosarcoma: a report from the Intergroup
Rhabdomyosarcoma Studies I to III. J Clin Oncol. 17:3468–3475.
1999.PubMed/NCBI
|
|
4
|
Koscielniak E, Morgan M and Treuner J:
Soft tissue sarcoma in children: prognosis and management. Paediatr
Drugs. 4:21–28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma WW and Adjei AA: Novel agents on the
horizon for cancer therapy. CA Cancer J Clin. 59:111–137. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Capdevila J, Elez E, Macarulla T, Ramos
FJ, Ruiz-Echarri M and Tabernero J: Anti-epidermal growth factor
receptor monoclonal antibodies in cancer treatment. Cancer Treat
Rev. 35:354–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab
plus irinotecan in irinotecan-refractory metastatic colorectal
cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herbst RS, Arquette M, Shin DM, Dicke K,
Vokes EE, Azarnia N, Hong WK and Kies MS: Phase II multicenter
study of the epidermal growth factor receptor antibody cetuximab
and cisplatin for recurrent and refractory squamous cell carcinoma
of the head and neck. J Clin Oncol. 23:5578–5587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vermorken JB: Squamous cell carcinoma of
the head and neck. J BUON. 7:311–317. 2002.PubMed/NCBI
|
|
10
|
Peng D, Fan Z, Lu Y, DeBlasio T, Scher H
and Mendelsohn J: Anti-epidermal growth factor receptor monoclonal
antibody 225 up-regulates p27KIP1 and induces
G1 arrest in prostatic cancer cell line DU145. Cancer
Res. 56:3666–3669. 1996.PubMed/NCBI
|
|
11
|
Wu X, Fan Z, Masui H, Rosen N and
Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor
receptor monoclonal antibody in a human colorectal carcinoma cell
line and its delay by insulin. J Clin Invest. 95:1897–1905. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perrotte P, Matsumoto T, Inoue K, Kuniyasu
K, Eve BY, Hicklin DJ, Radinsky R and Dinney CPN: Anti-epidermal
growth factor receptor antibody C225 inhibits angiogenesis in human
transitional cell carcinoma growing orthotopically in nude mice.
Clin Cancer Res. 5:257–265. 1999.PubMed/NCBI
|
|
13
|
Liu B, Fang M, Lu Y, Mendelsohn J and Fan
Z: Fibroblast growth factor and insulin-like growth factor
differentially modulate the apoptosis and G1 arrest induced by
anti-epidermal growth factor receptor monoclonal antibody.
Oncogene. 20:1913–1922. 2001. View Article : Google Scholar
|
|
14
|
Ciardiello F, Bianco R, Damiano V, De
Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR and
Tortora G: Antitumor activity of sequential treatment with
topotecan and anti-epidermal growth factor receptor monoclonal
antibody C225. Clin Cancer Res. 5:909–916. 1999.PubMed/NCBI
|
|
15
|
Kawaguchi Y, Kono K, Mimura K, Sugai H,
Akaike H and Fujii H: Cetuximab induce antibody-dependent cellular
cytotoxicity against EGFR-expressing esophageal squamous cell
carcinoma. Int J Cancer. 120:781–787. 2007. View Article : Google Scholar
|
|
16
|
Kimura H, Sakai K, Arao T, Shimoyama T,
Tamura T and Nishio K: Antibody-dependent cellular cytotoxicity of
cetuximab against tumor cells with wild-type or mutant epidermal
growth factor receptor. Cancer Sci. 98:1275–1280. 2007. View Article : Google Scholar
|
|
17
|
Kurai J, Chikumi H, Hashimoto K, Yamaguchi
K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M,
Nakamoto M, Burioka N and Shimizu E: Antibody-dependent cellular
cytotoxicity mediated by cetuximab against lung cancer cell lines.
Clin Cancer Res. 13:1552–1561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Naramura M, Gillies SD, Mendelsohn J,
Reisfeld RA and Mueller BM: Therapeutic potential of chimeric and
murine anti-(epidermal growth factor receptor) antibodies in a
metastasis model for human melanoma. Cancer Immunol Immunother.
37:343–349. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sato O, Wada T, Kawai A, Yamaguchi U,
Makimoto A, Kokai Y, Yamashita T, Chuman H, Beppu Y, Tani Y and
Hasegawa T: Expression of epidermal growth factor receptor, ERBB2
and KIT in adult soft tissue sarcomas: a clinicopathologic study of
281 cases. Cancer. 103:1881–1890. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ganti R, Skapek SX, Zhang J, Fuller CE, Wu
J, Billups CA, Breitfeld PP, Dalton JD, Meyer WH and Khoury JD:
Expression and genomic status of EGFR and ErbB-2 in alveolar and
embryonal rhabdomyosarcoma. Mod Pathol. 19:1213–1220. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Margue CM, Bernasconi M, Barr FG and
Schäfer BW: Transcriptional modulation of the anti-apoptotic
protein BCL-XL by the paired box transcription factors PAX3 and
PAX3/FKHR. Oncogene. 19:2921–2929. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laé M, Ahn EH, Mercado GE, Chuai S, Edgar
M, Pawel BR, Olshen A, Barr FG and Ladanyi M: Global gene
expression profiling of PAX-FKHR fusion-positive alveolar and
PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol.
212:143–151. 2007.PubMed/NCBI
|
|
25
|
Tomescu O, Xia SJ, Strezlecki D,
Bennicelli JL, Ginsberg J, Pawel B and Barr FG: Inducible
short-term and stable long-term cell culture systems reveal that
the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7
expression. Lab Invest. 84:1060–1070. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Taulli R, Scuoppo C, Bersani F, Accornero
P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M,
Crepaldi T and Ponzetto C: Validation of Met as a therapeutic
target in alveolar and embryonal rhabdomyosarcoma. Cancer Res.
66:4742–4749. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mercado GE, Xia SJ, Zhang C, Ahn EH,
Gustafson DM, Laé M, Ladanyi M and Barr FG: Identification of
PAX3-FKHR-regulated genes differentially expressed between alveolar
and embryonal rhabdomyosarcoma: focus on MYCN as a biologically
relevant target. Genes Chromosomes Cancer. 47:510–520. 2008.
View Article : Google Scholar
|
|
28
|
Williamson D, Lu YJ, Gordon T, Sciot R,
Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K and
Shipley J: Relationship between MYCN copy number and expression in
rhabdomyosarcomas and correlation with adverse prognosis in the
alveolar subtype. J Clin Oncol. 23:880–888. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taniguchi E, Nishijo K, McCleish AT,
Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman
SJ, Rubin BP and Keller C: PDGFR-A is a therapeutic target in
alveolar rhabdomyosarcoma. Oncogene. 27:6550–6560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Davicioni E, Anderson MJ, Finckenstein FG,
Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer
WH, Sorensen PHB and Triche TJ: Molecular classification of
rhabdomyosarcoma - genotypic and phenotypic determinants of
diagnosis: a report from the Children’s Oncology Group. Am J
Pathol. 174:550–564. 2009.PubMed/NCBI
|
|
31
|
Ebauer M, Wachtel M, Niggli FK and Schäfer
BW: Comparative expression profiling identifies an in vivo target
gene signature with TFAP2B as a mediator of the survival function
of PAX3/FKHR. Oncogene. 26:7267–7281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oda Y, Kohashi K, Yamamoto H, Tamiya S,
Kohno K, Kuwano M, Iwamoto Y, Tajiri T, Taguchi T and Tsuneyoshi M:
Different expression profiles of Y-box-binding protein-1 and
multidrug resistance-associated proteins between alveolar and
embryonal rhabdomyosarcoma. Cancer Sci. 99:726–732. 2008.
View Article : Google Scholar
|
|
33
|
Herrmann D, Seitz G, Warmann SW, Bonin M,
Fuchs J and Armeanu-Ebinger S: Cetuximab promotes immunotoxicity
against rhabdomyosarcoma in vitro. J Immunother. 33:279–286. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lièvre A, Bachet J-B, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier
P, Penault-Llorca F and Laurent-Puig P: KRAS mutation status is
predictive of response to cetuximab therapy in colorectal cancer.
Cancer Res. 66:3992–3995. 2006.PubMed/NCBI
|
|
35
|
Wellcome Trust Sanger Institute. Catalogue
of Somatic Mutations in Cancer. http://www.sanger.ac.uk/genetics/CGP/cosmic/.
Accessed June 4, 2012
|
|
36
|
Chen Y, Takita J, Hiwatari M, Igarashi T,
Hanada R, Kikuchi A, Hongo T, Taki T, Ogasawara M, Shimada A and
Hayashi Y: Mutations of the PTPN11 and RAS genes in
rhabdomyosarcoma and pediatric hematological malignancies. Genes
Chromosomes Cancer. 45:583–591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh
NT, Jackson S, Jackson C and Van Waes C: Effects of pharmacologic
antagonists of epidermal growth factor receptor, PI3K and MEK
signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF
expression in human head and neck squamous cell carcinoma lines.
Int J Cancer. 99:538–548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Raymond E, Faivre S and Armand JP:
Epidermal growth factor receptor tyrosine kinase as a target for
anticancer therapy. Drugs. 60(Suppl 1): 15–23. 2000. View Article : Google Scholar : PubMed/NCBI
|
